Emergence of AmpC beta-lactamases in isolates of Pseudomonas and Acinetobacter species, is a threatening condition as they mediate resistance to a wide variety of β-lactam drugs, including α-methoxy-β-lactams, such as cefoxitin, narrow-, expanded-and broad-spectrum cephalosporins, aztreonam and are poorly inhibited by β-lactam inhibitor combinations. The present study was conducted to determine the occurrence of blaampC genes in these pathogenic non-fermenters for their rapid and accurate detection. Monoplex PCR was done to detect blaampC genes in 40 non-duplicate clinical Pseudomonas and Acinetobacter isolates, that were found resistant to any of the third-generation cephalosporin and cefoxitin. Multiplex PCR assay was carried out to identify family-specific AmpC beta-lactamase genes within Pseudomonas and Acinetobacter spp. PCR detected blaampC in 43.24% of Pseudomonas and 33.33% of Acinetobacter isolates. Overall 42.50% of the total isolates were found to harbour blaampC genes by PCR. By multiplex PCR, total eight (20%) isolates yielded a positive amplicon with AmpCspecific primers. High prevalence of blaampC genes in cefoxitin-resistant isolates of Pseudomonas and Acinetobacter isolates emphasizes that molecular detection methods should be carried out to know the exact prevalence of beta-lactamases.
INTRODUCTION
Antibiotic resistance is now a linked global problem. It increases the morbidity, mortality and costs of treating infectious diseases. The threat from resistance (particularly multiple resistance in bacterial strains that have disseminated widely) has never been so great; however there are recent concerns about the increasing frequency of antibiotic resistance. The key factors driving this threat are increased antibiotic usage (in both human and animal medicine), greater movement of people and increased industrialization. The major forces behind the development of resistance in bacteria are exposure to antibiotics followed by selection and dissemination of resistant strains. The health care setting provides a favorable environment in this context. Resistant strains evolve and disseminate by direct and indirect contacts, where large numbers of people are congregated under one roof and where the usage of antibiotics is high. Therapeutic . options for infections caused by nosocomial isolates of Pseudomonas aeruginosa and Acinetobacter spp., expressing plasmid-mediated AmpC beta-lactamases are limited as these organisms are usually resistant to all beta-lactams except cefepime, cefpirome and carbapenams. Therefore, infection by these nosocomial isolates adversely affects clinical outcomes and patient treatment costs (Harris et al. 1999; Aloush et al. 2006) . Since the information on the molecular documentation of AmpC β-lactamases among Pseudomonas and Acinetobacter spp. are fragmentary in India; this study was carried to determine occurrence of bla ampC genes in these pathogenic non-fermenters for their accurate detection.
MATERIALS AND METHODS
The present prospective study was conducted in the department of Microbiology, J. N. Medical College, Aligarh Muslim University, Aligarh, during a period of one year (October 2010 to September 2011). Various clinical specimens received for routine culture and susceptibility testing in the clinical microbiology lab was studied. Clinical samples received in the laboratory were inoculated on the blood agar plate (BA) and teepol lactose agar (TLA) and then incubated overnight at 37 °C.
Pseudomonas and Acinetobacter spp were identified by different microbiologcal methods. Antibiotic susceptibility testing was done. 30µg cefoxitin disc was used for initial screening of AmpC beta-lactamase production. A total of forty isolates (23 Pseudomonas and 17 Acinetobacter spp.), that were found resistant to any of the third-generation cephalosporin and cefoxitin were randomly selected for molecular characterization.
Detection of bla ampC genes by monoplex PCR
The study isolates were subjected to PCR as described by Feria et al., (2002) with some modifications to detect bla ampC genes. AmpC-F-5'-CCCCGCTTATAGAGCAACAA-3' (634bp) and AmpC-R-5'-TCAATGGTCGACTTCACACC -3' primers were used. The reaction mixture was placed in MJ-mini Bio-Rad thermal cycler (Bio-Rad, USA). The PCR amplification cycle was performed with cycling conditions consisting of an initial denaturation step at 95˚C for 15 min, followed by 35 cycles of 94˚C for 60 sec., 58˚C for 2 min., 72˚C for 3 min. and the process was completed with a final elongation step at 72˚C for 10 min. Amplified PCR products were analysed by gel electrophoresis with 2% agarose (Bangalore Genei, India) gel containing ethidium bromide. After electrophoresis DNA fragments were visualized by Bio-Rad Gel documentation system (Bio-Rad, USA). Previously characterized isolates provided by Prof. Daniel Jonas, Germany, were used as positive controls.
Detection of plasmid-mediated AmpC β-lactamase by multiplex PCR
Multiplex PCR was carried out to detect family-specific plasmid-mediated AmpC β-lactamase genes by implementing protocol as described by Perez-Perez and Hanson (2002) . The total volume of reaction mixture was 25 µl (Table 1) . Primers were synthesised by Operon Biotechnologies, Cologne, Germany.
RESULTS AND DISCUSSION
As it is very crucial to know the exact prevalence of AmpC beta-lactamase harboring isolates of Pseudomonas and Acinetobacter spp., these isolates were subjected to genotypic detection by PCR. Table 2 shows that monoplex PCR detectedbla ampC in 43.24 % of Pseudomonas and 33.33% of Acinetobacter isolates. Overall 42.50% of the total isolates were found to harbour bla ampC genes by monoplex PCR (Figure 1 ). Multiplex PCR assay was carried out to identify family-specific AmpC beta-lactamase genes within Pseudomonas and Acinetobacter spp. As shown in table 2, total eight (20%) isolates yielded a positive amplicon with AmpC-specific primers.
Five isolates, out of total eight positive isolates corresponded to the MOX-family, while only one isolate belonged to CIT-family. Rest 2 isolates were confirmed to be of FOXfamily. Two distinct bands were noticed in only one isolate, which belonged to the genus Pseudomonas. In the isolate showing two bands in multiplex PCR, the upper band corresponded to the CIT family and the lower band was obtained at 200bp, which corresponds to the expected position of the FOX family (Figure 2) . To identify the exact family to which lower band belongs, monoplex PCR was done for all the families of AmpC β-lactamases and an amplified product corresponding to EBC family was obtained. Apart from fragmentary reports regarding the prevalence of AmpC beta-lactamases in Pseudomonas and Acinetobacter spp, the actual prevalence is still unknown, as most of these studies are based on phenotypic detection methods only. One important fact is that, there is currently no clear consensus regarding guidelines for phenotypic screening or confirmatory tests for AmpC β-lactamaseproducing organisms (Shahid et al., 2004) . Our study reveals high prevalence of bla ampC (42.50%) among clinically important Pseudomonas and Acinetobacter isolates from our centre. In contrary to our results, from North India, 20 % of P. aeruginosa (Delhi) and 20.7 % of Gram-negative organisms (Aligarh) and 47.8% E. coli, 17.3% P. aeruginosa, 13% K. pneumoniae (Kolkata) were reported as AmpC β-lactamase producers (Manchanda and Singh, 2003; Shahid et al., 2003; Suranjana and Manjusri, 2005) . 37.50% isolates have been reported as AmpCproducers from Chennai (Subha et al., 2003) .
In another study performed by Singhal et al. (2005) , prevalence of AmpC β-lactamases was reported as 8%, which is much lower than our finding in Pseudomonas and Acinetobacter spp. In 2007, Hemlatha et al., from Chennai reported 47.3% AmpC-producers in Escherichia coli and Klebsiella isolates. In 2010, Upadhyay et al., from Varanasi, reported 59.4% isolates of P. aeruginosa as AmpC-producers. In the same year, Mohamudha et al. (2010) , reported 93.6% Gram-negative clinical isolates as AmpC-producers, based on three-dimensional extract method. They reported 66.6% and 55.5% plasmid-mediated AmpCproducers in Acinetobacter and Pseudomonas respectively. 33 (32.7%) isolates of Pseudomonas aeruginosa were confirmed to be positive for AmpC beta-lactamase, in study conducted by kumar et al. in 2012. Similar results were reported by Sreeshma et al. in 2013 where 48% of isolates were inducible AmpC producers and only 2% produced plasmid mediated AmpC beta-lactamase. Oteo et al., (2010) from Spain have reported the occurrence of plasmidmediated bla ampC in 38% isolates. Tan et al. (2009) detected bla ampC in 47% isolates. In a study carried out by Shahid et al. (2009 ) in Aligarh between 2003 .1% of isolates belonging to family Enterobacteriaceae, were found to carry bla ampC genes. In a recent study conducted in Iran 60.8% of tha Pseudomonas aeruginosa isolates harbored bla ampC (Roya et al., 2014) .
CONCLUSION
The detection of bla ampC reflects the emergence of betalactamases among antimicrobial resistant Pseudomonas and Acinetobacter isolates. The present study also highlights that molecular methods should be carried out in clinical laboratories to know the accurate prevalence of beta-lactamases, so that effective steps can be taken to prevent the further spread of these resistant strains. 
